Abstract
Asenapine (ASN) monotherapy is approved for the acute treatment of manic or mixed episodes associated with bipolar I disorder in pediatric patients (10 to 17 years). Weight gain is a common side effect with atypical antipsychotic use and it is important to identify baseline characteristics that may predispose patients to it. This post hoc analysis examined whether weight gain was related to baseline body mass index (BMI) in pediatric patients treated with ASN.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Journal of the American Academy of Child & Adolescent Psychiatry
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
